Crossmark

Therapy of nodal Follicular Lymphoma (WHO grade 1/2) in clinical stage I/II using response adapted Involved Site Radiotherapy in combination with Obinutuzumab (Gazyvaro) - GAZAI Trial (GAZyvaro and response adapted Involved-site Radiotherapy): a study protocol for a single-arm, non-randomized, open, national, multi-center phase II trial

Crossref DOI link: https://doi.org/10.1186/s13063-019-3614-y

Published Online: 2019-08-30

Published Print: 2019-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

König, Laila https://orcid.org/0000-0001-8402-6694
Dreyling, Martin

Dürig, Jan

Engelhard, Marianne

Hohloch, Karin

Viardot, Andreas

Witzens-Harig, Mathias

Kieser, Meinhard

Klapper, Wolfram

Pott, Christiane

Herfarth, Klaus
License Information

Text and Data Mining valid from 2019-08-30

Version of Record valid from 2019-08-30
More Information

Article History

Received: 7 December 2018

Accepted: 24 July 2019

First Online: 30 August 2019

Ethics approval and consent to participate

: The Heidelberg Ethics Committee approved this study on June 6, 2016 (AFmu-316/2017). Consent to participate/informed consent will be obtained from all participants in the study.Central ethical approval has been confirmed from the Heidelberg Ethics Committee (reference approval number: AFmu-316/2017) and we will not begin recruiting at other centers in the trial until local ethical approval has been obtained.

: Not applicable

: The authors declare that they have no competing interests.

Document is current

Any future updates will be listed below